James R. Gatherwright

James R. Gatherwright

Auto-generated profile, based on publicly available information

James R. Gatherwright

Division of Plastic Surgery, MetroHealth Medical Center, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
JGJames R. Gatherwright
James R. Gatherwright
YWYuewei Wu-Fienberg
Yuewei Wu-Fienberg
BGBahman Guyuron
Bahman Guyuron

12 July 2021 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
CCChristopher Cheng
Christopher Cheng
GKGrzegorz J. Kwiecien
Grzegorz J. Kwiecien
DRDavid James Rowe
David James Rowe
JGJames R. Gatherwright
James R. Gatherwright
KCKyle J. Chepla
Kyle J. Chepla
Summary: Injectable drug use in the upper extremity often leads to chronic wounds complicated by osteomyelitis. Conventional reconstructive options are often not feasible and/or are contraindicated in this patient population. We have started using a synthetic, biodegradable temporizing matrix (BTM) for the treatment of these patients. We hypothesize that BTM is a safe, low-risk, and low-morbidity alternative reconstructive option. We report outcomes after staged debridement and BTM application followed by split-thickness skin grafting for two patients with large, chronic bilateral forearm wounds with concomitant osteomyelitis confirmed by MRI and biopsy. No acute surgical complications were encountered and at a mean follow-up of 13 months, both patients had maintained stable soft-tissue coverage. Reconstruction using BTM is a novel treatment option that can simplify the reconstruction, reduce donor-site morbidity, and optimize success for patients with chronic wounds resulting from injectable drug use. Initial outcomes are promising; however, further comparative studies are needed to better evaluate long-term outcomes of this technique.

23 February 2019 in European Journal of Plastic Surgery
Verified
Journal Article
Open access
PDF file
RKRebecca Knackstedt
Rebecca Knackstedt
RDRisal Djohan
Risal Djohan
JGJames Gatherwright
James Gatherwright
Microsurgical breast reconstruction patients are at an increased risk for venous thromboembolism (VTE) due to numerous risk factors. A meta-analysis focusing on anti-thrombotics in breast microsurgery has yet to be completed. We aimed to perform a systematic review of the literature to examine the effects of thromboprophylaxis in breast microsurgical reconstruction with a focus on patient and flap complications. A PubMed, Cochrane, and Medline database search was conducted with the following keywords: “venous thrombosis, thromboprophylaxis, mechanical, pneumatic compression, aspirin, heparin, dextran, ketorolac, toradol, warfarin, and coumadin.” Results were combined with the terms “breast microsurgery” and “breast free flap.” All articles that resulted were analyzed. The reference list for each included article was analyzed for other applicable articles. Only articles that addressed pre-operative or post-operative anti-coagulation were included. For data analysis, if the article reported that there were no flap complications, it was assumed there were no operative hematomas, vessel thrombosis, or flap loss. Two hundred and fifty-seven studies were screened from the abovementioned search results and 17 fit inclusion criteria. The majority of included studies were retrospective chart reviews and the type of thromboprophylaxis and its effect on complications was rarely the primary end point. Due to lack of reporting on patient and flap characteristics that could impact outcomes, subgroup analysis was impossible. There has yet to be a consensus on the most effective way to prevent VTE in women undergoing microsurgical breast reconstruction without increasing the risk of hematoma and flap compromise. Studies published to date vary in their thromboprophylatic regimens and rarely include a control or comparison group to allow for intra- or inter-group analysis. There is a need for well-done, randomized, controlled trials in order to determine the best approach to thromboprophylaxis in these patients.